FURTHER DEFINITION OF THE D-1 DOPAMINE-RECEPTOR PHARMACOPHORE - SYNTHESIS OF 8,9,13B-HEXAHYDRO-5H-BENZO[D]NAPHTH[2,1-B]AZEPINES AS RIGID ANALOGS OF BETA-PHENYLDOPAMINE
K. Negash et al., FURTHER DEFINITION OF THE D-1 DOPAMINE-RECEPTOR PHARMACOPHORE - SYNTHESIS OF 8,9,13B-HEXAHYDRO-5H-BENZO[D]NAPHTH[2,1-B]AZEPINES AS RIGID ANALOGS OF BETA-PHENYLDOPAMINE, Journal of medicinal chemistry, 40(14), 1997, pp. 2140-2147
In an effort to define further the active geometry of the beta-phenyld
opamine pharmacophore of certain dopamine D1 agonists, the title compo
unds have been synthesized as conformationally restricted homologues o
f the potent benzophenanthridine dopamine D1 agonist dihydrexidine 4a,
The dihydroxy secondary amine 5b was evaluated as a potential agonist
, whereas the N-methyl compounds 5a and 5c were hypothesized to be ant
agonists, Surprisingly, none of the three compounds had high affinity
for dopamine D1 or D2 receptors. A comparison of the low-energy confor
mations of these molecules shows that the pendant phenyl ring of 5b is
twisted about 28 degrees relative to that of the corresponding ring o
f 4a. Further, the additional methylene used to expand the C ring of 5
b projects toward the a face of the molecule, perhaps suggesting that
steric protrusion in this region of the molecule is not tolerated. Fin
ally, the phenethylamine fragment incorporated into these molecules de
viates about 30 degrees from the antiperiplanar conformation postulate
d to be necessary for agonist activity, On the other hand, the potenti
al antagonist molecules 5a and 5c were compared with the dopamine D1 a
ntagonist SCH 39166 2. The conformations of the former two structures
differ quite dramatically from that of 2. The most notable differences
lie in the relative orientations of the pendant phenyl rings in the t
wo series, as well as the fact that the ethylamine fragment in 2 appro
ximates a gauche conformation, while the comparable orientation in 5a
and 5c more nearly approaches an antiperiplanar conformation. These fi
ndings will be used to refine further the model of the dopamine D1 ago
nist receptor that we have previously developed.